This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Oncology, Other  • Prognosis/ Outcomes  • Liver/ Biliary Tract/ Pancreatic Diseases  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Kenneth S. Chok, MBBS; Kelvin K. Ng, PhD; Ronnie T. P. Poon, MS; Chi Ming Lam, MS; Jimmy Yuen, MBBS; Wai Kuen Tso, MBBS; Sheung Tat Fan, MS, MD, PhD

Arch Surg. 2006;141:1231-1236.

Hypothesis  The survival benefits of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) are similar for patients with unresectable hepatocellular carcinoma amenable to either treatment.

Design  Retrospective comparative study.

Setting  Tertiary care institution.

Patients  From February 22, 2001, to March 10, 2004, 91 patients with unresectable hepatocellular carcinoma (tumor diameter <5 cm and <4 tumor nodules) treated by either TACE or RFA were analyzed from a prospective database.

Main Outcome Measures  The treatment-related morbidity, mortality, overall survival, and time to disease progression.

Results  Forty patients received TACE and 51 patients received RFA during the study period. Demographic data were comparable in both groups of patients. The treatment-related morbidities of TACE and RFA were 10% and 28%, respectively (P = .04). There was no treatment-related mortality in either group. There was 1 patient (2%) with complete tumor remission in the TACE group, and the complete ablation rate in the RFA group was 96%. The time to disease progression was similar in both groups (P = .95). The overall survival rates at 1 and 2 years were 80% and 58%, respectively, in the TACE group and 82% and 72%, respectively, in the RFA group (P = .21).

Conclusions  The overall survival and time for disease progression were similar in both groups of patients. In terms of the survival result, the efficacies of RFA and TACE were comparable for patients with unresectable hepatocellular carcinoma.

Author Affiliations: Departments of Surgery (Drs Chok, Ng, Poon, Lam, and Fan) and Radiology (Drs Yuen and Tso), Centre for the Study of Liver Disease, University of Hong Kong, Pokfulam, Hong Kong.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intraoperative Radiofrequency Ablation for Hepatocellular Carcinoma: Long-Term Results in a Large Series
Kim et al.
Ann. Surg. Oncol. 2008;15:1862-1870.
ABSTRACT | FULL TEXT